RUNX1 and acute myeloid leukemia: In a large study of 664 AML patients treated on two phase 3 trials conducted by the German AML Cooperative Group, mutations in RUNX1, SRSF2, U2AF1, and SF3B1 were found to be independent risk factors for achievement of CR112.